News

Bristol Myers Squibb's Growth Portfolio Just Hit $7.7 Billion. Is This Cheap Pharma Stock a No-Brainer Buy?

NASDAQ

Key PointsBristol Myers Squibb has an attractive 4.3% yield, and its P/E is below average for a drug maker.

Read the full Veytics brief

We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.